These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19450979)

  • 21. Hammerhead ribozymes with cleavage site specificity for NUH and NCH display significant anti-hepatitis C viral effect in vitro and in recombinant HepG2 and CCL13 cells.
    Gonzalez-Carmona MA; Schüssler S; Serwe M; Alt M; Ludwig J; Sproat BS; Steigerwald R; Hoffmann P; Quasdorff M; Schildgen O; Caselmann WH
    J Hepatol; 2006 Jun; 44(6):1017-25. PubMed ID: 16469406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Riboproteomic analysis of polypeptides interacting with the internal ribosome-entry site element of foot-and-mouth disease viral RNA.
    Pacheco A; Reigadas S; Martínez-Salas E
    Proteomics; 2008 Nov; 8(22):4782-90. PubMed ID: 18937254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Expression of secreted alkaline phosphatase in hepatocytes controlled by HCV IRES].
    Liu SP; Tan DM; Hou ZH
    Hunan Yi Ke Da Xue Xue Bao; 2003 Aug; 28(4):335-7. PubMed ID: 14653111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oligonucleotide-based strategies to inhibit human hepatitis C virus.
    Martinand-Mari C; Lebleu B; Robbins I
    Oligonucleotides; 2003; 13(6):539-48. PubMed ID: 15025918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationship of new anti-hepatitis C virus agents: heterobicycle-coumarin conjugates.
    Neyts J; De Clercq E; Singha R; Chang YH; Das AR; Chakraborty SK; Hong SC; Tsay SC; Hsu MH; Hwu JR
    J Med Chem; 2009 Mar; 52(5):1486-90. PubMed ID: 19193060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human initiation factor eIF3 subunit b interacts with HCV IRES RNA through its N-terminal RNA recognition motif.
    Pérard J; Rasia R; Medenbach J; Ayala I; Boisbouvier J; Drouet E; Baudin F
    FEBS Lett; 2009 Jan; 583(1):70-4. PubMed ID: 19059401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term hepatitis C internal ribosome entry site-dependent gene expression mediated by phage phiC31 integrase in mouse model.
    Sun Z; Wang Y; Fu Q; Zhou Y; Jia S; Du J; Peng J; Wang Y; Yang S; Zhan L
    Antivir Ther; 2009; 14(3):393-400. PubMed ID: 19474473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative analysis of intracellular trans-splicing ribozyme activity against hepatitis C virus internal ribosome entry site.
    Ryu KJ; Lee SW
    J Microbiol; 2004 Dec; 42(4):361-4. PubMed ID: 15650696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect.
    Kanda T; Steele R; Ray R; Ray RB
    J Virol; 2007 Jan; 81(2):669-76. PubMed ID: 17079316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TAT peptides mediated small interfering RNA delivery to Huh-7 cells and efficiently inhibited hepatitis C virus RNA replication.
    Meng S; Wei B; Xu R; Zhang K; Wang L; Zhang R; Li J
    Intervirology; 2009; 52(3):135-40. PubMed ID: 19478527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Convert hepatitis C virus into a non-enveloped virus like hepatitis A, by targeting its envelope rather than the RNA.
    Helmy A
    Med Hypotheses; 2006; 66(4):847-50. PubMed ID: 16229965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Catalytic metallodrugs targeting HCV IRES RNA.
    Bradford S; Cowan JA
    Chem Commun (Camb); 2012 Mar; 48(25):3118-20. PubMed ID: 22343977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oligonucleotide-based therapeutic options against hepatitis C virus infection.
    Trepanier JB; Tanner JE; Alfieri C
    Antivir Ther; 2006; 11(3):273-87. PubMed ID: 16759043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation of RNA aptamers specific for the HCV minus-IRES domain I.
    Konno K; Nishikawa S; Hasegawa T; Fukuda K
    Nucleic Acids Symp Ser (Oxf); 2007; (51):393-4. PubMed ID: 18029752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [BMS-790 052 - an oral antiviral hepatitis C antiviral in the pipeline].
    Schmitz J
    Pharm Unserer Zeit; 2011 Jan; 40(1):8-9. PubMed ID: 21194074
    [No Abstract]   [Full Text] [Related]  

  • 36. A cell-based bicistronic lentiviral reporter system for identification of inhibitors of the hepatitis C virus internal ribosome entry site.
    Lourenço S; Boni S; Furling D; Cosset FL; Cahour A
    J Virol Methods; 2009 Jun; 158(1-2):152-9. PubMed ID: 19428584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small interfering RNA targeted to stem-loop II of the 5' untranslated region effectively inhibits expression of six HCV genotypes.
    Prabhu R; Garry RF; Dash S
    Virol J; 2006 Nov; 3():100. PubMed ID: 17129382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific inhibition of hepatitis C viral gene expression by non-polar (phenylalkyl)phosphonates.
    Amberg S; Tamke A; Caselmann WH; Engels JW
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1631-4. PubMed ID: 14565483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An atypical IRES within the 5' UTR of a dicistrovirus genome.
    Roberts LO; Groppelli E
    Virus Res; 2009 Feb; 139(2):157-65. PubMed ID: 18755228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphorothioate antisense oligodeoxynucleotides capable of inhibiting hepatitis C virus gene expression: in vitro translation assay.
    Seki M; Honda Y
    J Biochem; 1995 Dec; 118(6):1199-204. PubMed ID: 8720135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.